Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 158

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 2
Chunk 158
---
and warranties and certain covenants and agreements would not be satisfied; (vii) by the Company in the event (A) (1) MultiplAI
or any of the MultiplAI Shareholders breaches or violates any representation, warranty, covenant, agreement or obligation contained in
the MultiplAI SPA, subject to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions
relating to representations and warranties and certain covenants and agreements contained in the MultiplAI SPA would not be satisfied,
(2) of a MultiplAI Material Adverse Effect, or (3) of a breach of any representation, warranty, covenant or agreement set forth
in the Business Combination Agreement on the part of MultiplAI, subject to certain exceptions and cure periods set forth in the Business
Combination Agreement, such that the conditions relating to representations and warranties and certain covenants and agreements would
not be satisfied, and (B) the Company exercises its right to cause the Parent to terminate the MultiplAI SPA and the MultiplAI SPA
is not terminated following the expiration of certain cure periods; and (viii) by the Company if the SEC Required Financials shall
not have been delivered by OmnigenicsAI or MultiplAI, on or prior to the applicable deadline specified in the Business Combination Agreement.

 34

In the event that the
Business Combination Agreement is terminated, all Transaction Expenses incurred in connection with the Proposed Business Combination shall
be paid by the party incurring such Transaction Expenses. If the Transactions are consummated, (a) OmnigenicsAI shall pay or cause
to be paid (i) the SPAC Transaction Expenses, subject to the SPAC Transaction Expenses Cap, and (ii) the Company Transaction
Expenses at the Closing; and (b) Templar Sponsor shall pay or cause to be paid, (i) all unpaid SPAC Transaction Expenses in
excess of the applicable SPAC Transaction Expenses Cap, (ii) any expenses incurred by the Company in its pursuit of potential acquisition
or business targets other than the Target Companies or that were not incurred by the Company in connection with or in furtherance of the
Proposed Business Combination and (c) all fees and expenses incurred by the Company solely relating to the extension proposals approved
by the shareholders of the Company on February 27, 2023, September 7, 2023 and December